Citius Pharmaceuticals (CTXR) vs NewcelX (NCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NewcelX (NCEL) has outperformed Citius Pharmaceuticals (CTXR) over the past year, losing 22.3% versus a loss of 55.4%. Over five years, CTXR leads with a -98.8% price change compared with -99.7% for NCEL. NewcelX is the larger company by market cap ($14.7 million vs $14.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTXR | NCEL |
|---|---|---|
| Share price | $0.5085 | $2.54 |
| Market cap | $13.96M | $14.67M |
| 1-day change | +2.27% | -5.58% |
| YTD return | -34.56% | +33.68% |
| 1-year return | -55.39% | -22.32% |
| 5-year return | -98.79% | -99.65% |
| P/E ratio (TTM) | — | 4.88 |
| EPS (TTM) | $-1.75 | $0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-39.74M | $-8.30M |
| 52-week high | $1.54 | $5.12 |
| 52-week low | $0.37 | $1.83 |
| Distance from 52-week high | -66.98% | -50.39% |
| Analyst consensus | none | none |
| Avg. price target upside | +686.63% | +805.51% |
| Average volume | 275.44K | 13.34K |
| Shares outstanding | 27.45M | 5.78M |
| Employees | 23 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NCEL has outperformed CTXR by 33.1 percentage points over the past year.
About Citius Pharmaceuticals
CTXR stock →Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About NewcelX
NCEL stock →NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
CTXR vs NCEL FAQ
Which is bigger, Citius Pharmaceuticals or NewcelX?
NewcelX (NCEL) is larger, with a market capitalization of $14.67M compared with $13.96M for Citius Pharmaceuticals (CTXR).
Which stock has performed better over the past year, CTXR or NCEL?
NCEL returned -22.32% over the past 12 months, compared with -55.39% for CTXR (price return, excluding dividends). Past performance does not predict future results.
Are Citius Pharmaceuticals and NewcelX in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.